ATTRALUS
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
ATTRALUS
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.attralus.com
Total Employee:
11+
Status:
Active
Total Funding:
197 M USD
Technology used in webpage:
Euro U.S. Server Location
Similar Organizations
Clade Therapeutics
Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Samaritan Pharmaceuticals Inc
Samaritan is a biopharmaceutical company focusing on commercializing therapeutic products that relieve the suffering of patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Advisors List
Current Employees Featured
Founder
Investors List
venBio Partners
venBio Partners investment in Series B - Attralus
Sarissa Capital Management
Sarissa Capital Management investment in Series B - Attralus
Vivo Capital
Vivo Capital investment in Series B - Attralus
Logos Capital
Logos Capital investment in Series B - Attralus
Surveyor Capital
Surveyor Capital investment in Series B - Attralus
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series B - Attralus
Alpha Wave Ventures
Alpha Wave Ventures investment in Series B - Attralus
Sarissa Capital Management
Sarissa Capital Management investment in Series B - Attralus
venBio Partners
venBio Partners investment in Series B - Attralus
Logos Capital
Logos Capital investment in Series B - Attralus
Key Employee Changes
| Date | New article |
|---|---|
| 2021-05-10 | Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives |
Official Site Inspections
http://www.attralus.com Semrush global rank: 5.21 M Semrush visits lastest month: 1.49 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Attralus"
Company | Attralus
Attralus aims to transform the lives of patients with amyloidosis with therapeutics that remove toxic amyloid. We are advancing a pipeline of novel biologics designed for pan-amyloid removal – across all stages and types of systemic …See details»
Novel Pan-Amyloid Removal (PAR) Therapeutics | Attralus
Nov 12, 2024 Attralus is developing novel pan-amyloid removal (PAR) therapeutics that are designed to eliminate toxic, disease-causing amyloid in organs and tissues of patients with …See details»
Attralus - Crunchbase Company Profile & Funding
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to …See details»
Attralus Company Profile | Management and Employees List
Attralus headquarters are located in 329 Oyster Point Blvd Fl 3, South San Francisco, California, 94080, United States . What are Attralus’s primary industries? Attralus’s main industries are: …See details»
Contact Us - Attralus
Attralus, Inc. | San Francisco, CA | Contact | Biopharmaceutical Company | Systemic Amyloidosis | 50 Francisco St, San Francisco, CA 94133See details»
Working At Attralus: Company Overview and Culture - Zippia
Our mission is to improve the lives of amyloidosis patients by developing transformational therapeutics focused on amyloid removal. Based in South San Francisco, CA, Attralus is a …See details»
Attralus Company Profile 2024: Valuation, Funding
Attralus General Information Description. Developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatments. The company specializes in developing immunotherapies to clear …See details»
Attralus - Funding, Financials, Valuation & Investors - Crunchbase
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients. Search Crunchbase. Start Free Trial . ... How much funding has …See details»
Attralus, Inc. Company Profile | Burlingame, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Attralus, Inc. of Burlingame, CA. Get the latest business insights from Dun & Bradstreet.See details»
Attralus Company Profile - Office Locations, Competitors ... - Craft
Attralus is a company that develops immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatment. The company specializes in the …See details»
Attralus - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Attralus . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of Board …See details»
Attralus - Overview, News & Similar companies | ZoomInfo.com
Jun 8, 2022 Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) BURLINGAME, Calif., …See details»
A Brief History of Attralus - CBM
Oct 2, 2024 Attralus is a pioneering company in the field of medical technology, revolutionizing the way diseases are diagnosed and treated. Founded in 2010 by a team of brilliant minds …See details»
Attralus - Work in biotech
Attralus is developing methods to diagnose and treat patients with systemic amyloid diseases. There are currently no treatments to remove toxic amyloid from patients with systemic …See details»
Mission, Vision & Core Values of Attralus – CBM
Oct 2, 2024 Attralus is dedicated to revolutionizing the field of healthcare through its unwavering commitment to its mission, vision, and core values. Our mission is to provide cutting-edge …See details»
Science - Attralus
Attralus is advancing the amyloidosis treatment paradigm by developing first-in-class therapies using our proprietary pan-amyloid removal (PAR) technology. With our differentiated …See details»
Attralus Closes $56 Million Financing - BioSpace
Feb 6, 2024 About Attralus Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. …See details»
Attralus Therapeutic AT-02 Receives Orphan Drug Designation …
Naples, FL – November 12, 2024 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with …See details»
Pipeline - Attralus
124 I-evuzamitide (AT-01) is the first non-invasive pan-amyloid PET imaging agent specifically designed for systemic amyloidosis. 124 I-evuzamitide utilizes the company’s pan-amyloid …See details»
News - Attralus
Nov 12, 2024 Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the …See details»